Acalabrutinib for MCL, CLL & SLL Treatment, Benefits & India Supply

Home >> Article >> Acalabrutinib for MCL, CLL & SLL Treatment, Benefits & India Supply

Acalabrutinib for MCL, CLL & SLL Treatment, Benefits & India Supply

Acalabrutinib for MCL, CLL & SLL: Complete Treatment Guide

Acalabrutinib (brand name Calquence, also written acalabrutinib 100mg) is a second-generation, highly selective Bruton's tyrosine kinase (BTK) inhibitor. It is used to treat mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), and small lymphocytic lymphoma (SLL). This therapeutic drug is taken orally as one 100 mg capsule or tablet twice daily, roughly 12 hours apart.

Ikris Pharma Network is a trusted supplier and exporter from India. We facilitate legitimate access to acalabrutinib for patients, hospitals, wholesalers, and distributors worldwide, including support for named-patient supply where permitted by local law. Acalabrutinib is a prescription-only oncology drug and must be used under the proper supervision of an experienced hematologist or oncologist.

Need acalabrutinib bulk supply or pricing? Contact Ikris Pharma Network with your destination country to receive guidance on availability, brands, and lawful import options.

Key Facts About Acalabrutinib:

Generic name: Acalabrutinib
Brand name: Calquence
Drug class: BTK (Bruton's tyrosine kinase) inhibitor — second generation
Strength / form: 100 mg capsule and 100 mg film-coated tablet
Standard dose: 100 mg twice daily, ~12 hours apart, with or without food
Approved for: MCL, CLL, and SLL (in eligible adult patients)
First FDA approval: October 2017 (MCL); expanded to CLL/SLL in November 2019
Supplier / Exporter from India: Ikris Pharma Network

What is Acalabrutinib and how Does it Work?

Acalabrutinib is a targeted cancer therapy, not traditional chemotherapy. It works by blocking Bruton's tyrosine kinase (BTK), a signalling protein inside B-lymphocytes that drives the growth, survival, and movement of malignant B-cells. Acalabrutinib and its active metabolite, ACP-5862, form a covalent (irreversible) bond with a cysteine residue in the BTK active site, switching the enzyme off and slowing cancer progression.

Acalabrutinib is described as a second-generation BTK inhibitor. Compared with the first-generation BTK inhibitor ibrutinib, it was designed for higher selectivity for BTK with fewer off-target effects, which is associated with a more favourable tolerability profile. At the standard 100 mg twice-daily dose, near-complete BTK occupancy in the blood is maintained across the full dosing interval.

Mantle Cell Lymphoma (MCL) and Acalabrutinib:

Mantle cell lymphoma (MCL) is an uncommon, aggressive subtype of B-cell non-Hodgkin lymphoma that arises from cells in the "mantle zone" of the lymph node. It often presents at an advanced stage with enlarged lymph nodes, an enlarged spleen, bone-marrow involvement, and sometimes gastrointestinal involvement.

Acalabrutinib was first approved by the US FDA in October 2017 for adults with MCL who had received at least one prior therapy. In the pivotal phase 2 ACE-LY-004 study, single-agent acalabrutinib produced a high overall response rate in patients with relapsed or refractory MCL, with most side effects being mild to moderate. Acalabrutinib has since also been approved in several regions, including India, for previously untreated MCL in eligible patients, often in combination regimens. It is recognised in major oncology treatment guidelines as a preferred option for previously treated MCL.

Mantle Cell Lymphoma (MCL) Treatment in India:

Mantle cell lymphoma (MCL) treatment in India is delivered through a well-developed oncology and hematology ecosystem that includes targeted oral therapies such as BTK inhibitors, immunotherapy, chemo-immunotherapy, and stem-cell transplantation at specialist cancer centres. Acalabrutinib is part of the modern targeted-therapy toolkit used by hematologists for eligible MCL patients. As an acalabrutinib supplier from India, Ikris Pharma Network supports access to therapy for patients prescribed acalabrutinib by their treating oncologist, for patients across the world through lawful supply channels.

Chronic Lymphocytic Leukemia (CLL) and Acalabrutinib:

Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in adults. It is a slow-growing cancer in which the bone marrow produces too many abnormal B-lymphocytes that accumulate in the blood, bone marrow, and lymph nodes.

Acalabrutinib was approved by the US FDA for CLL in November 2019, based on trials in both previously untreated patients (ELEVATE-TN) and relapsed/refractory patients (ASCEND). It can be used as a single agent or in combination with other agents.

In February 2026, the FDA approved acalabrutinib in combination with venetoclax as the first all-oral, fixed-duration (approximately 14-month) BTK-inhibitor-based regimen for adults with previously untreated CLL or SLL, based on the phase 3 AMPLIFY trial. This is an important development because it offers a defined treatment duration rather than continuous indefinite therapy for eligible first-line patients.

Small Lymphocytic Lymphoma (SLL) and Acalabrutinib:

Small lymphocytic lymphoma (SLL) is essentially the same disease as CLL but is classified as a lymphoma because the cancerous cells are found mainly in the lymph nodes and lymphoid tissue rather than circulating in large numbers in the blood. Because CLL and SLL share the same biology, they are treated similarly.

Acalabrutinib is approved for SLL alongside CLL, including the newer fixed-duration acalabrutinib-plus-venetoclax combination for eligible previously untreated patients. The same 100 mg twice-daily oral dosing applies.

Acalabrutinib Dosing, Formulations, and Administration:

Standard dose: 100 mg twice daily (a total of 200 mg per day), taken about 12 hours apart, with or without food.
Swallow whole: Capsules and tablets should be swallowed whole with water and not crushed, chewed, or dissolved.
Capsule vs. tablet: Both 100 mg formulations are bioequivalent. The tablet can be taken together with acid-reducing medicines (proton-pump inhibitors, H2 blockers, antacids), whereas the capsule has restrictions on co-administration with acid reducers.
Supervision: Treatment should be started and monitored by a physician experienced in cancer therapy.

Note: Dosing may be adjusted or interrupted by the prescribing physician based on side effects, other medicines, and individual patient factors. Always follow your oncologist's instructions.

Important Safety Information:

Acalabrutinib is generally considered well tolerated relative to older BTK inhibitors, but it can cause serious side effects. Reported risks include serious and sometimes opportunistic infections, bleeding events, cardiac arrhythmias such as atrial fibrillation and flutter, low blood counts (cytopenias including neutropenia, anemia, and thrombocytopenia), and second primary cancers, including skin cancers. Common milder effects can include headache, diarrhea, fatigue, and muscle aches.

This medicine is prescription-only and is not suitable for everyone. Patients should discuss their full medical history, current medications, pregnancy or breastfeeding status, and planned surgeries with their oncologist before and during treatment.

Acalabrutinib Supplier and Exporter from India: How Ikris Pharma Network Helps

India is one of the world's leading sources of high-quality, affordable medicines and a major hub for pharmaceutical exports. For patients and healthcare providers searching for an acalabrutinib exporter from India, Ikris Pharma Network provides:

Prescription-based access to acalabrutinib (acalabrutinib 100mg) for eligible patients, with verification of a valid prescription.
Named-patient supply support for international patients, arranged in compliance with the import and prescription laws of the destination country.
Guidance on availability, brands, and acalabrutinib pricing for hospitals, clinics, distributors, and individual patients.
Oral oncology logistics with documentation support for lawful cross-border supply.
Responsive patient and physician support throughout the access process.

Ikris Pharma Network operates as a facilitator of legitimate, prescription-led access. Acalabrutinib should only be obtained and used under the care of a licensed oncologist or hematologist. We do not supply prescription medicines without appropriate prescription documentation.

To request acalabrutinib supply, pricing, or export

information, contact Ikris Pharma Network (IPN) with your prescription details and destination country.

What is acalabrutinib used for?

Acalabrutinib is used to treat adults with mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), and small lymphocytic lymphoma (SLL). It is a BTK inhibitor that slows the growth of cancerous B-cells.

Who is the acalabrutinib supplier and exporter from India?

Ikris Pharma Network is an acalabrutinib supplier and exporter from India that facilitates legitimate, prescription-based access to acalabrutinib for patients, hospitals, and distributors worldwide.

What is the standard dose of acalabrutinib?

The standard dose is 100 mg twice daily (about 12 hours apart), taken with or without food. It is available as a 100 mg capsule and a 100 mg tablet.

Is acalabrutinib the same as Calquence?

Yes. Calquence is the brand name for the generic medicine acalabrutinib.

How is acalabrutinib different from ibrutinib?

Acalabrutinib is a second-generation BTK inhibitor designed to be more selective for BTK than the first-generation inhibitor ibrutinib, which is associated with fewer off-target side effects.

Is mantle cell lymphoma (MCL) treatment available in India?

Yes. Mantle cell lymphoma (MCL) treatment in India is available at specialist cancer and hematology centres and includes targeted oral therapies such as BTK inhibitors, chemo-immunotherapy, and stem-cell transplantation. Ikris Pharma Network supports access to prescribed acalabrutinib for eligible patients.

Can I buy acalabrutinib without a prescription?

No. Acalabrutinib is a prescription-only oncology medicine and must be used under the supervision of a qualified oncologist or hematologist. A valid prescription is required for supply.

Can acalabrutinib be exported from India to other countries?

Acalabrutinib can be supplied internationally through lawful, prescription-based channels such as named-patient programs, subject to the import and prescription regulations of the destination country. Ikris Pharma Network supports this process.

About Ikris Pharma Network:

Ikris Pharma Network is an India-based pharmaceutical supplier and exporter focused on access to specialty and oncology medicines, including BTK inhibitors such as acalabrutinib. We support patients, physicians, hospitals, and distributors with legitimate, prescription-led access and documentation for lawful international supply.

Medical Disclaimer:

This article is for general educational and informational purposes only and is not medical advice. It does not replace consultation with a qualified healthcare professional. Acalabrutinib is a prescription-only medicine with potentially serious side effects, and treatment decisions must be made by a licensed oncologist or hematologist who knows the patient's full medical history. Always seek professional medical advice before starting, stopping, or changing any treatment.

By Ikris Pharma Network — Acalabrutinib Supplier and Exporter from India

Last updated: June 2026 · Medically reviewed content for informational purposes only

References:

07-07-2026

Written By:

nitin